Loading
Each trial would set its target mix of patients from cancer registry data on who gets that cancer, by age, sex and ethnicity, and show a public running tally so gaps are visible while there is still time to fix them.
Sponsors derive enrolment targets per stratum from incidence data (SEER, GLOBOCAN, national registries) for the indication and the countries where the trial runs, publish the targets in the registry record, and update enrolled counts quarterly. Recruitment resources are reallocated during the trial toward under-enrolled strata (site additions, navigators, translated materials).
One bottleneck page and 14 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Patients are not the bottleneck; trial access is. Bringing trials to community practices, loosening restrictive eligibility criteria and reducing site burden would do more for enrolment than patient education. Trials today reflect the minority of patients who happen to be treated where trials exist.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, GLOBOCAN / Global Cancer Observatory, SEER (Surveillance, Epidemiology, and End Results), ClinicalTrials.gov.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.
Shares Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes, Trials enrol too few, too slowly.
Shares Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018, Trials do not represent the people who get cancer.
Shares ClinicalTrials.gov, Trials do not represent the people who get cancer, Trials enrol too few, too slowly.